Infliximab (Remicade, Remsima, Inflectra)
Measured alone or as part of a profile including anti-Infliximab antibodies.
Assay also measures biosimilars Remsima and Inflectra.
This test is not currently included in the laboratory's UKAS scope of accreditation to ISO15189:2012.
Please use drug levels as a guide. Infliximab Interpretation:
- Therapeutic drug levels: ≥2.5 µg/mL
- Intermediate drug levels: 1.2 – 2.4 µg/mL
- Subtherapeutic drug levels: < 1.2 µg/mL
Test interpretation requires full clinical information: drug dosage/frequency, previous exposure to other biologics, time of sampling, duration of therapy and clinical assessment.
Collect blood into a serum separation (SST™) or plain tube, preferably shortly before drug administration (trough levels). Centrifuge sample at 3000 rpm for 10 minutes, aliquot serum or plasma and keep in fridge until transport. If transport is going to be delayed by > 5 days, freeze at -20°C and send by first class post at a later date.
St Thomas' Hospital
Westminster Bridge Road
London SE1 7EH
Last updated: 18/12/2020